Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: replimune.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/23/2025 | $2.00 | Outperform → Underperform | BMO Capital Markets |
7/23/2025 | Buy → Neutral | H.C. Wainwright | |
7/23/2025 | $3.00 | Overweight → Equal Weight | Barclays |
7/22/2025 | $3.00 | Outperform → Market Perform | Leerink Partners |
7/22/2025 | $9.00 | Overweight → Neutral | Analyst |
7/22/2025 | $4.00 | Outperform → Neutral | Wedbush |
7/22/2025 | $3.00 | Overweight → Neutral | Piper Sandler |
6/20/2025 | Overweight | Cantor Fitzgerald | |
8/28/2024 | $17.00 | Buy | ROTH MKM |
4/17/2023 | $44.00 | Overweight | Piper Sandler |
DEFA14A - Replimune Group, Inc. (0001737953) (Filer)
DEF 14A - Replimune Group, Inc. (0001737953) (Filer)
8-K - Replimune Group, Inc. (0001737953) (Filer)
8-K - Replimune Group, Inc. (0001737953) (Filer)
S-3 - Replimune Group, Inc. (0001737953) (Filer)
S-3 - Replimune Group, Inc. (0001737953) (Filer)
S-8 - Replimune Group, Inc. (0001737953) (Filer)
10-K - Replimune Group, Inc. (0001737953) (Filer)
8-K - Replimune Group, Inc. (0001737953) (Filer)
SCHEDULE 13G/A - Replimune Group, Inc. (0001737953) (Subject)
BMO Capital Markets downgraded Replimune from Outperform to Underperform and set a new price target of $2.00
H.C. Wainwright downgraded Replimune from Buy to Neutral
Barclays downgraded Replimune from Overweight to Equal Weight and set a new price target of $3.00
Leerink Partners downgraded Replimune from Outperform to Market Perform and set a new price target of $3.00
Analyst downgraded Replimune from Overweight to Neutral and set a new price target of $9.00
Wedbush downgraded Replimune from Outperform to Neutral and set a new price target of $4.00
Piper Sandler downgraded Replimune from Overweight to Neutral and set a new price target of $3.00
Cantor Fitzgerald initiated coverage of Replimune with a rating of Overweight
ROTH MKM initiated coverage of Replimune with a rating of Buy and set a new price target of $17.00
Piper Sandler resumed coverage of Replimune with a rating of Overweight and set a new price target of $44.00
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The CRL indicates that the FDA is unable to approve the application in its present form. The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial eviden
WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 16 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 32,135 shares of the Company's common stock and restricted stock units representing an aggregate of 64,320 s
WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 10 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 36,485 shares of the Company's common stock and restricted stock units representing an aggregate of 41,080 s
- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were generally well tolerated - WOBURN, Mass., June 01, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented two posters highlighting data updates for RP1 (vusolimogene oderparepvec) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago. "The new analyses we pres
WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 4:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering th
• BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete • Full commercial infrastructure for launch in place ahead of July 22nd PDUFA date • Conference call today at 8:00 AM ET WOBURN, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2025 and provided a business update. "As we near our PDUFA date, our commercial organization is now fully hired and ready to execute our fir
WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025. Fiscal Fourth Quarter Earnings Replimune will release its fiscal year end earnings and host a conference call at 8:00 a.m. ET on May 22, 2025. Listeners can register for the webcast via this link. Analysts wishing to participate in the
WOBURN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 18 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 21,960 shares of the Company's common stock and restricted stock units representing an aggregate of 44,005 sh
Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha
WOBURN, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 53 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregate of 98,450 shares of the Company's common stock and restricted stock units representing an aggregate of 155,875 shares of the Company's common stock. Each option has an exercise price of $7.49 per share, w
Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha
Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Sushil Patel, Ph.D., will succeed Philip
The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complexCompany backed by leading venture firms, BioGeneration Ventures (BGV) and ForbionWorld-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in s
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms. Hill was most recently CFO of the commercial stage biotech company PTC Therapeutics and has more than 15 years of experience in the biotechnology and life sciences industry having held senior financial management and investor relations roles at several leading public biotechnology and pharmaceutical companies. "Emily brings a wealth of financial planning and strategy experience to Replimune that will be impactfu
Mr. Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer's fully integrated $20 billion healthcare business Mr. Weinand is a seasoned business leader with over 25 years of experience leading business and strategic operations for companies including Bayer, Pfizer, Bristol Myers Squibb, Sanofi, and Otsuka Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Mr. Dieter Weinand to its board of directors, effective immediately. Coya will leverage Mr. Weinand's extens
Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License Application submission anticipated in Q1/2 2024 Cost sharing collaboration in cutaneous squamous cell carcinoma in the neoadjuvant setting entered into with Incyte Data snapshot for all 141 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma expected Q4 2023 RP2 and RP3 Phase 2 programs; third-line colorectal cancer clinical trial initiated, first- and second-line hepatocellular carcinoma trials expected to initiate this quarter; Phase 1 clinical trial
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced the appointment of Veleka R. Peeples-Dyer to the Company's Board of Directors effective June 1, 2023. "We are pleased to welcome Veleka to Replimune's Board of Directors," said Philip Astley-Sparke, Chief Executive Officer of Replimune. "Veleka is a highly accomplished life sciences executive, experienced attorney and compliance professional with over 24 years of her practice dedicated to the life sciences industry assisting with building legal and compliance
NAARDEN, Netherlands and MUNICH, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, announces the appointment of Silva Deželan PhD, as Forbion's first Head of Impact & ESG. Silva has over 15 years of experience in ESG integration, sustainability and impact investing, including private equity, most recently as ESG Director at Stafford Capital Partners and before that as Director, Sustainability, Private Equity at Robeco. Silva contributes her knowledge of ESG best-practice to a number of professional organizations, including as vice-chair of Invest Europe's ESG Committee, and as a member of the Responsible Investment Committee of the Du
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), announced today the appointment of Christopher Sarchi as Replimune's Chief Commercial Officer and the appointment of Sushil Patel, Ph.D., previously Replimune's Chief Commercial Officer, to a newly created position of Chief Strategy Officer, effective immediately. "These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 commercial launch of RP1," said Philip Astley-Sparke, C
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company's Board of Directors effective December 1, 2021. "We are delighted to welcome Christy to Replimune's Board of Directors," said Philip Astley-Sparke, Chief Executive Officer of Replimune. "Christy brings nearly 30 years of commercial and business experience in the pharmaceutical and biotechnology industry foremostly in oncology. We look forward to working with Christy and believe her guidance and input will strengthen our
WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025. Fiscal Fourth Quarter Earnings Replimune will release its fiscal year end earnings and host a conference call at 8:00 a.m. ET on May 22, 2025. Listeners can register for the webcast via this link. Analysts wishing to participate in the
Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of pat
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial and new data from first 30 patients with anti-PD1 failed non-melanoma skin cancers in IGNYTE trial adds to growing body of evidence supporting the potential of RP1 in difficult to treat skin cancer s
The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including: Topline data from the CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinomaAn initial data snapshot for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanomaInitial data from the IGNYTE cohort of RP1 in anti-PD1 failed non-melanoma skin cancersA recap of interim data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant recipients with skin cancer recently presented at SITC 2023 WOBURN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)